Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib and Zimberelimab in advanced biliary tract cancer
NCT07710885Phase 3Recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Apr 2030
- Countries
- 4
01
Overview
A Phase 3 trial of futibatinib, zimberelimab in biliary tract cancer (BTC), sponsored by Taiho Pharmaceutical Co., Ltd.. Started Jun 2026; status: recruiting.
02
Drugs
futibatinibzimberelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07710885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710885.